TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Phase 2 Terminated 12 enrolled H. Lee Moffitt Cancer Center and Research Institute TG Therapeutics, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see how safe and effective the investigational drug umbralisib (TGR-1202) is in individuals with Chronic Lymphocytic Leukemia (CLL)

Timeline

Start: 2019-11-12
Primary completion: 2022-10-19
Completion: 2022-10-19

Publications

Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Umbralisib	Small molecule	800 mg	Oral

TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Summary

Timeline

Publications

Drugs

Indications